ResearchObstetricsMedication use during pregnancy, with particular focus on prescription drugs: 1976-2008
Section snippets
Birth Defects Study
Since 1976, the Boston University Slone Epidemiology Center BDS has interviewed mothers of infants with any major structural birth defects recruited from birth and tertiary care hospitals in a number of regional study centers (Boston, MA; Philadelphia, PA; Toronto, Canada; the state of Iowa, and San Diego, CA) as well as through birth defects registries in Massachusetts and New York State.
Beginning in 1993, a sample of mothers of infants without birth defects has also been included from each
All medications (OTC and prescription medications combined)
For the 33 year BDS study, Figure 1 presents secular patterns of use of any medication at any time during pregnancy as well as any medication taken in the first trimester. Overall, the average number used any time in pregnancy increased by 68%, from 2.5 in 1976-1978 to 4.2 in 2006-2008 (range, 0–28); in the last year, 93.9% took at least 1 medication. During the first trimester, the average number of medications increased during those same years by 62.5%, from 1.6 to 2.6 (range, 0–25); 82.3% of
Comment
The US Collaborative Perinatal Project reported the use of specific prescription and OTC medications in more than 50,000 women drawn from 12 study centers.14 However, those data, collected between 1957 and 1963, have limited relevance to current patterns. Other data, from more recent decades, have been subject to important limitations. Two studies conducted in the 1980s were small and focused on geographically limited populations over periods of only 22 or 6 years.3 Much larger datasets, drawn
Acknowledgment
We wish to thank Dr Margaret Honein for her support and guidance.
References (19)
- et al.
Use of prescription and non-prescription drugs in pregnancy
Clin Epidemiol
(1993) - et al.
Prescription drug use in pregnancy
Am J Obstet Gynecol
(2004) - et al.
Use of over-the-counter medications in pregnancy
Am J Obstet Gynecol
(2005) - et al.
Medication in early pregnancy: Prevalence of use and relationship to maternal characteristics
Am J Obstet Gynecol
(1991) - et al.
Drug prescription in pregnancy: analysis of a large statutory sickness fund population
Eur J Clin Pharamacol
(2004) - et al.
Patterns of medication use during and prior to pregnancy: the MAP study
Aust N Z J Obstet Gynecol
(2000) Studies of drug-induced birth defects
- et al.
Pharmacovigilance in pregnancy using population-based linked datasets
Pharamcoepidemiol Drug Saf
(2009) - et al.
Herbal use before and during pregnancy
Am J Obstet Gynecol
(2010)
Cited by (597)
Prescription medication use during pregnancy in the United States from 2011 to 2020: trends and safety evidence
2024, American Journal of Obstetrics and GynecologyEvaluation of a microphysiological human placental barrier model for studying placental drug transfer
2024, Reproductive ToxicologyCommon teratogenic medication exposures—a population-based study of pregnancies in the United States
2024, American Journal of Obstetrics and Gynecology MFMHow the structural determinants of health inequities impact access to prescription medication for pregnant women in Australia: a narrative review
2024, The Lancet Regional Health - Western PacificEthical and Legal Obligations for Research Involving Pregnant Persons in a Post-Dobbs Context
2023, Journal of Law, Medicine and Ethics
Cite this article as: Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1-8.
Reprints not available from the authors.
This study was supported in part by Cooperative Agreement no. U50/CCU113247 with the Centers for Disease Control and Prevention through the Massachusetts Department of Public Health, Cooperative agreements under program announcement no. 02081 from the Centers for Disease Control and Prevention to the centers participating in the National Birth Defects Prevention Study, and Grant R01 HD 046595 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
The views expressed herein are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.